Last updated: May 21, 2026
Executive summary: Lotrimin Ultra is a topical antifungal cream formulation of clotrimazole marketed for superficial fungal skin infections. Public information ties “Lotrimin Ultra” to clotrimazole-based OTC topical products; the drug’s commercial trajectory is governed primarily by genericized ingredient-level IP and product-formulation manufacturing constraints rather than long-running, drug-substance exclusivity. Clinical development activity for “Lotrimin Ultra” as a branded product is not supported by identifiable, current US pivotal trials in public registries; commercial outcomes track OTC category share, channel pricing, and competitive intensity from clotrimazole and alternative antifungals. Patent and exclusivity exposure is short in practice because clotrimazole is a long-established active ingredient.
Which clinical trials involve LOTRIMIN ULTRA (clotrimazole) and what is the latest update?
Direct answer: No current, clearly identifiable clinical trial record in US registries (ClinicalTrials.gov) specifically for “Lotrimin Ultra” as a branded investigational program is available in the public record. Public registries primarily reflect generic drug studies, bioequivalence work for specific clotrimazole topical formulations, or academic antifungal studies rather than branded “Lotrimin Ultra” development.
Are there any new US trials for clotrimazole topical “Lotrimin Ultra” formulations?
- No publicly indexed Phase 2/3 efficacy or safety trials for a branded “Lotrimin Ultra” investigational product are indicated in the public record.
- The most common trial types for established topical actives like clotrimazole are:
- formulation equivalence and stability programs (rarely indexed as interventional efficacy trials),
- vehicle and penetration/mechanism studies (often academic, not branded),
- OTC switch or labeling-support studies that are not always presented as late-stage registrational trials.
What does “clinical trials update” mean for an OTC clotrimazole brand?
For OTC topical products, the most decision-relevant “trial updates” are usually:
- postmarketing safety surveillance signals,
- new label indications or regimen guidance,
- comparative effectiveness evidence that changes prescribing habits even when the active ingredient is generic.
For Lotrimin Ultra specifically, no clear late-stage registrational update is supported by publicly indexed branded trial data.
What is LOTRIMIN ULTRA’s market size, growth drivers, and category outlook for clotrimazole topical antifungals?
Direct answer: The relevant market is the US OTC topical antifungal category for superficial mycoses (tinea pedis, tinea corporis, ringworm, athlete’s foot, and similar indications). Demand is driven by:
- recurrence cycles and chronic exposure risk (athletics, footwear, communal facilities),
- OTC convenience and household penetration,
- substitution among azoles, allylamines, and combination antifungals.
Market drivers that typically move clotrimazole topical performance
- Price-to-value pressure: clotrimazole faces strong cost competition from generics and private label.
- Preference for regimens and vehicles: creams, sprays, and “ultra” style claims often map to perceived efficacy, absorption, or convenience.
- Formulation differentiation: even with generic ingredient access, packaging, texture, and dosing guidance can influence shelf share.
Competitive landscape that matters for Lotrimin Ultra
Key competitive groups:
- other OTC azoles: miconazole, econazole-like agents depending on availability,
- allylamines: terbinafine (often strong efficacy perceptions),
- combination products: antifungal plus corticosteroid (where allowed and appropriate),
- branded “targeted” line extensions in the same at-home fungal care segment.
How does “ultra” positioning impact shelf economics?
“Ultra” naming typically functions as a differentiated SKU within an OTC line and impacts:
- planogram placement,
- couponing and promotions,
- perceived efficacy tiering against standard creams.
In practice, SKU-level differentiation competes inside an ingredient-similar set, so category growth lifts all players while share gains require either retailer execution or meaningful vehicle/regimen advantage.
What is the patent and exclusivity status for LOTRIMIN ULTRA (clotrimazole) in the US Orange Book?
Direct answer: Lotrimin Ultra is an OTC topical clotrimazole product and is not expected to have a corresponding FDA Orange Book record as a separately approved prescription drug application. Orange Book listings attach to approved drug products under an NDA/ANDA. OTC topical products of established actives are frequently not represented in the Orange Book unless there is an NDA/ANDA-based approval structure for the specific marketed strength/form.
What does this imply for exclusivity timelines?
- Any effective exclusivity for “Lotrimin Ultra” is not substrate-level exclusivity like 5-year New Chemical Entity or 7-year orphan-type exclusivity.
- Practical market protection is usually:
- trademark/brand differentiation (not patent exclusivity),
- formulation/manufacturing trade secrets,
- formulation patents that would show up only if the specific marketed product is linked to a patent-protected approved application (often not applicable to legacy OTC topical products).
Which patents protect clotrimazole topical products like LOTRIMIN ULTRA, and how many are typically relevant?
Direct answer: For established topical azoles like clotrimazole, protection is usually limited and fragmented:
- foundational composition-of-matter patents are long expired,
- modern coverage, when any exists, is typically around formulation/vehicle, specific concentrations, film-forming or penetration-enhancing excipients, or specific dosing/regimen methods.
For a brand like Lotrimin Ultra, meaningful US patent coverage would depend on whether a current, enforceable formulation patent exists covering the exact cream composition and manufacturing process. Public IP enforcement for clotrimazole topical creams is typically low visibility and does not map cleanly to one consolidated estate for the brand name.
How formulation patents can still matter even when clotrimazole is generic
Even if ingredient-level patents expired, formulation patents can still:
- constrain generic re-formulation if claim elements are specific to excipient selection or manufacturing steps,
- create litigation leverage in certain jurisdictions if a marketed product copies a protected formulation archetype.
When does LOTRIMIN ULTRA lose exclusivity and what generic entry risks exist?
Direct answer: For OTC clotrimazole topical creams, “loss of exclusivity” is effectively already realized at the ingredient level. Generic entry risk is structural and ongoing because:
- clotrimazole is widely available as a commodity active,
- multiple generic manufacturers can produce therapeutically equivalent topical antifungal creams.
Generic entry risk profile
- High baseline risk at the active ingredient level: substitution across clotrimazole brands is straightforward.
- Moderate SKU-specific constraints: if a brand has a protected formulation, then a generic entrant would need either licensing or a design-around.
- Low evidentiary friction: OTC topical products can often change via market competition without new FDA approvals that require Orange Book linkage.
What FDA regulatory status applies to LOTRIMIN ULTRA (NDA, ANDA, monograph, OTC status)?
Direct answer: Lotrimin Ultra is marketed as an OTC topical antifungal. This typically places it under OTC drug regulation frameworks rather than an NDA/ANDA product approval sequence captured by the Orange Book.
How OTC regulation affects clinical and market timing
- There is often no NDA lifecycle with exclusivity extensions.
- The regulatory constraint is compliance with monograph expectations (where applicable) and manufacturing/labeling rules.
- Competitive entry can be faster than for prescription drugs.
What market forecast should be used for LOTRIMIN ULTRA and how to project revenue under realistic share assumptions?
Direct answer: A practical projection approach uses the clotrimazole topical antifungal segment as the anchor, then applies an OTC “brand/SKU share” sensitivity model driven by:
- retailer listing dynamics,
- promotional intensity,
- substitution by terbinafine-like options and other azoles.
Because “Lotrimin Ultra” is an OTC brand-level SKU, revenue projection is most sensitive to channel share, price per unit, and promotional discount rate rather than to R&D-driven clinical milestones.
Scenario framework (projection logic)
Use three cases for the next 3 to 5 years:
- Base case (category growth, flat-to-slight share): revenue grows in-line with category inflation and modest unit expansion.
- Downside (share pressure from alternative azoles/allylamines): unit share declines, promotions increase to defend shelf.
- Upside (vehicle advantage + retailer execution): regained shelf placement or higher conversion improves share.
Key metrics to model at SKU level
- Unit sales (treat as the primary driver)
- Net price after promotions
- Gross margin change (driven by ingredient and manufacturing costs)
- Trade spend and retailer fees
- Pack size mix shift
Actionable market projection inputs
For internal planning, the decision-useful input is not a one-number forecast, but the share sensitivity:
- A 1 percentage-point shift in OTC shelf share typically moves revenue more than a small category growth adjustment.
- Promotional frequency and couponing determine whether the brand maintains higher net price.
How does LOTRIMIN ULTRA compare with competing OTC topical antifungals (clotrimazole vs terbinafine vs miconazole)?
Direct answer: The market compares across active class performance perceptions and regimen convenience. Terbinafine is often viewed as more effective for some tinea infections due to shorter courses, while clotrimazole competes on breadth of indications, OTC familiarity, and retail availability.
Switching behavior that affects Lotrimin Ultra performance
- Patients and retailers may switch based on:
- time-to-clearance perceptions,
- cost per treatment,
- ease of application,
- prior experience and outcomes.
Positioning implications
If Lotrimin Ultra’s “ultra” differentiation maps to perceived penetration or comfort, it can mitigate some substitution losses. If differentiation is mostly naming and packaging, it tends to be overwhelmed by price and promotions.
What patent litigation or settlement agreements affect LOTRIMIN ULTRA?
Direct answer: No specific, ongoing or recently reported patent litigation centered on “Lotrimin Ultra” as a brand is identifiable from public, consolidated records. For established topical clotrimazole actives, litigation (when it occurs) is usually:
- ingredient/formulation patent enforcement by the most relevant private-label or formulation holder,
- disputes between formulation innovators and generic entrants tied to a specific claimed composition.
Clinical development vs commercial execution: what should R&D, BD, and investors track next?
Direct answer: Since branded clinical development is not evident in public trial registries for “Lotrimin Ultra,” decision tracking should focus on:
- OTC shelf share and retailer placements,
- competitive promo calendars and net price trajectory,
- any formulation patent filings that map to the exact marketed vehicle,
- label and regimen updates from market-leading antifungal competitors.
Key Takeaways
- Lotrimin Ultra is an OTC topical clotrimazole brand; ingredient-level exclusivity is effectively exhausted.
- Public registries do not show a clear current branded “Lotrimin Ultra” Phase 2/3 clinical development program.
- Market outcomes are primarily determined by OTC category dynamics, shelf execution, and competitive substitution rather than by new clinical milestones.
- Patent and exclusivity risk for generic entry is structurally high at the clotrimazole ingredient level; any remaining protection would likely be limited to narrow formulation/vehicle or manufacturing claims, if present.
- Revenue projection should be built on SKU share sensitivity (units, net price, promotions), not on clinical pipeline timelines.
FAQs
- Is Lotrimin Ultra listed in the FDA Orange Book and does it have NDA/ANDA exclusivity?
- How long do formulation patents typically last for OTC topical clotrimazole creams?
- Do clotrimazole topical creams compete mainly on efficacy or on time-to-clearance versus terbinafine?
- What are the main regulatory pathways and compliance requirements for OTC antifungal creams in the US?
- What data best predicts OTC antifungal SKU performance: market share, coupon rate, or treatment cost per course?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- ClinicalTrials.gov. Database of privately and publicly funded clinical studies. National Library of Medicine.
- FDA. OTC Drug Products: OTC Monograph System and related guidance. U.S. Food and Drug Administration.
